Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals REGN.

And retail traders should know.

We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.

Today, Benzinga's options scanner spotted 8 options trades for Regeneron Pharmaceuticals.

This isn't normal.

The overall sentiment of these big-money traders is split between 37% bullish and 62%, bearish.

Out of all of the options we uncovered, there was 1 put, for a total amount of $49,380, and 7, calls, for a total amount of $489,368.

Expected Price Movements

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $620.0 to $980.0 for Regeneron Pharmaceuticals over the recent three months.

Analyzing Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Regeneron Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Regeneron Pharmaceuticals's substantial trades, within a strike price spectrum from $620.0 to $980.0 over the preceding 30 days.

Regeneron Pharmaceuticals Option Activity Analysis: Last 30 Days

Noteworthy Options Activity:

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

After a thorough review of the options trading surrounding Regeneron Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Regeneron Pharmaceuticals's Current Market Status

• Trading volume stands at 92,111, with REGN's price up by 0.14%, positioned at $967.49.
• RSI indicators show the stock to be may be approaching overbought.
• Earnings announcement expected in 62 days.

Professional Analyst Ratings for Regeneron Pharmaceuticals

Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $1075.25.

• Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1082.
• An analyst from RBC Capital persists with their Outperform rating on Regeneron Pharmaceuticals, maintaining a target price of $1110.
• An analyst from Cantor Fitzgerald persists with their Neutral rating on Regeneron Pharmaceuticals, maintaining a target price of $925.
• An analyst from RBC Capital persists with their Outperform rating on Regeneron Pharmaceuticals, maintaining a target price of $1184.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.